Skip to main content
TipRanks
Go Ultimate75% OFF

Vivesto AB (VIVE) AI Stock Analysis

0 Followers
SE:VIVE

Vivesto AB

(Nasdaq OMX AB:VIVE)

Select Model
Rating:41Neutral
Price Target:SEK 7.00▼(-1.96% Downside)
Action:upgraded
Date:10/08/26

The score is held down primarily by weak financial performance: Vivesto generates no revenue, posts continued losses (-SEK 31.5 million TTM) and negative free cash flow, leaving it reliant on capital markets and pipeline success. The main offset is a clean, debt-free balance sheet with SEK 158 million of equity funding 94% of assets and a sharply reduced burn rate, which provides a reasonable runway. Technicals add further pressure, with the share trading below all major moving averages and a negative MACD, although extremely oversold RSI and Stochastic readings leave room for a short-term rebound. Valuation offers no support given negative earnings and no dividend. Earnings call and corporate event data were unavailable and excluded, with their weight redistributed across the remaining components.

Positive Factors
Low leverage and equity cushionA debt-free balance sheet and substantial equity cushion give Vivesto greater financial flexibility than a highly leveraged development-stage biotech. This can support continued research investment and help absorb operating losses, although preserving that cushion depends on improving operations or securing funding.
Negative Factors
Near-zero revenue baseNear-zero reported revenue shows that Vivesto has not yet established a recurring commercial business capable of funding operations. Until a candidate is approved, partnered on meaningful terms, or commercialized, financial performance remains heavily dependent on development progress and available capital.

Vivesto AB (VIVE) vs. iShares MSCI Sweden ETF (EWD)

-60%-40%-20%0%20%40%SE:VIVE-43.03%EWD+16.08%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
SEK 79.05M
Dividend Yield
―
Average Volume (3M)
7,683
Price to Earnings (P/E)
-5.3
Beta (1Y)
0.56
Revenue Growth
―
EPS Growth
37.35%
Country
Sweden
Employees
4
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Vivesto AB Business Overview & Revenue Model

Company Description

Vivesto AB, established in 1988 and headquartered in Solna, Sweden, specializes in the development, production, commercialization, and sale of pharmaceutical products within human and veterinary oncology, primarily operating in its home country. Its...

How the Company Makes Money

Vivesto AB’s revenue model is primarily that of a development-stage biopharmaceutical company: it seeks to create shareholder value and future earnings by advancing oncology drug candidates through preclinical and clinical development toward regulato...

Vivesto AB Financial Statement Overview

Summary

Vivesto is a pre-commercial, clinical-stage pharma with essentially no revenue since 2022, resulting in a very weak income statement (score 19) with a TTM operating loss of SEK 31.5 million and slightly negative gross profit. Cash flow remains negative (score 32), though operating outflow has narrowed sharply from -SEK 146 million in 2021 to -SEK 29.6 million TTM. The balance sheet is the key offset (score 61): the company is debt-free, equity of SEK 158.3 million funds about 94% of total assets, and capital was recently replenished, implying a multi-year runway at the current burn. Offsetting this, equity has eroded from SEK 550 million in 2021, return on equity is about -22%, and the company remains dependent on external funding and pipeline execution.

Income Statement

19Very Negative

Balance Sheet

61Positive

Cash Flow

32Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue00001.01M26.19M
Gross Profit-478.00K0-3.19M0-10.66M-17.93M
EBITDA-31.00M-34.38M-36.56M-123.79M-100.56M-99.77M
Net Income-31.54M-34.08M-39.75M-128.74M-367.03M-138.94M
Balance Sheet
Total Assets168.56M149.04M172.88M220.67M355.88M594.31M
Cash, Cash Equivalents and Short-Term Investments23.51M2.10M32.29M77.04M142.51M97.27M
Total Debt013.00M008.17M10.43M
Total Liabilities10.30M24.46M14.55M22.87M30.45M44.59M
Stockholders Equity158.26M124.58M158.33M197.80M325.42M549.71M
Cash Flow
Free Cash Flow-24.64M-43.81M-47.25M-69.40M-80.79M-179.91M
Operating Cash Flow-29.64M-33.96M-47.25M-68.74M-80.52M-145.56M
Investing Cash Flow-18.55M21.85M43.40M63.73M-45.28M118.65M
Financing Cash Flow48.94M13.00M00128.76M-5.81M

Vivesto AB Technical Analysis

Technical Analysis SentimentNegative
Last Price7.14

Price Trends

50DMA7.86Negative
100DMA8.31Negative
200DMA8.53Negative

Market Momentum

MACD-0.15Negative
RSI43.47Neutral
STOCH26.29Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:VIVE, the sentiment is Negative. The current price of 7.14 is below the 20-day moving average (MA) of 7.34, below the 50-day MA of 7.86, and below the 200-day MA of 8.53, indicating a bearish trend. The MACD of -0.15 indicates Negative momentum. The RSI at 43.47 is Neutral, neither overbought nor oversold. The STOCH value of 26.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:VIVE.

Vivesto AB Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

SE:VIVE against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SE:NANEXASE:NANEXA67NeutralSEK 1.90B12.9887.15%―2370.13%―
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
SE:NICASE:NICA46NeutralSEK 57.37M0.5023.67%―163.58%―
SE:SPAGOSE:SPAGO42NeutralSEK 35.13M-1.05-87.37%―-97.52%31.31%
SE:VIVESE:VIVE41NeutralSEK 79.05M-5.32-20.29%――37.35%
SE:SPECSE:SPEC40UnderperformSEK 19.12M-0.31-25.90%――78.15%
SE:CLS.BSE:CLS.B38UnderperformSEK 78.99M-1.17-66.41%―-47.42%44.01%

* Healthcare Sector Average

Performance Comparison

0%200%400%600%SE:VIVESE:CLS.BSE:SPECSE:NICASE:SPAGOSE:NANEXADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SE:VIVE and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SE:VIVEVivesto AB7.14-7.10-49.86%
SE:CLS.BClinical Laserthermia Systems AB Class B1.58-5.16-76.53%
SE:SPECSpectraCure AB0.01-0.11-90.08%
SE:NICANanologica AB0.17-0.83-82.70%
SE:SPAGOSpago Nanomedical AB0.04-0.06-59.00%
SE:NANEXANanexa AB9.928.23486.98%

Vivesto AB Corporate Events

Vivesto’s Paccal Vet Data Spotlighted at Key Veterinary Oncology Conference

Sep 24, 2026

Vivesto AB announced that topline data from its Paccal Vet clinical studies in dogs and cats are being presented in two posters at the Veterinary Cancer Society Annual Conference 2026 in Minneapolis, reinforcing the company’s growing presence in vete...

Vivesto’s Paccal Vet Shows Promising Efficacy and Safety in Feline Cancer Study

Sep 17, 2026

Vivesto AB has reported positive topline results from its dose-finding study of Paccal Vet in cats with solid tumors, showing clear indications of anti-tumor activity across multiple tumor types. The trial enrolled 21 cats and identified biological r...

Vivesto’s Paccal Vet Shows Survival Benefit in Canine Hemangiosarcoma Study

Sep 15, 2026

Vivesto AB has reported positive topline results from an open-label pilot study of its veterinary cancer drug candidate Paccal Vet in dogs with Stage I-II splenic hemangiosarcoma following splenectomy. The median overall survival of 135 days exceeded...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 08, 2026